Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Impact of germinal center-associated nuclear protein polymorphisms on breast cancer risk and prognosis in a Japanese population.

Kotani H, Ito H, Kuwahara K, Kuzushima K, Iwata H, Tsunoda N, Nagino M, Matsuo K.

Breast Cancer. 2019 Sep;26(5):562-572. doi: 10.1007/s12282-019-00956-5. Epub 2019 Feb 27.

PMID:
30810967
2.

Improving TCR affinity on 293T cells.

Ohta R, Demachi-Okamura A, Akatsuka Y, Fujiwara H, Kuzushima K.

J Immunol Methods. 2019 Mar;466:1-8. doi: 10.1016/j.jim.2018.11.010. Epub 2018 Nov 22.

3.

Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S.

Stem Cell Reports. 2018 Jun 5;10(6):1935-1946. doi: 10.1016/j.stemcr.2018.04.025. Epub 2018 May 24.

4.

Highly functional T-cell receptor repertoires are abundant in stem memory T cells and highly shared among individuals.

Miyama T, Kawase T, Kitaura K, Chishaki R, Shibata M, Oshima K, Hamana H, Kishi H, Muraguchi A, Kuzushima K, Saji H, Shin-I T, Suzuki R, Ichinohe T.

Sci Rep. 2017 Jun 16;7(1):3663. doi: 10.1038/s41598-017-03855-x.

5.

Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells.

Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, Fujii S.

Cancer Res. 2016 Jul 1;76(13):3756-66. doi: 10.1158/0008-5472.CAN-15-3219.

6.

A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.

Casey NP, Fujiwara H, Tanimoto K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

PLoS One. 2016 Jun 7;11(6):e0156896. doi: 10.1371/journal.pone.0156896. eCollection 2016.

7.

Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.

Takamatsu H, Araki R, Nishimura R, Yachie A, Espinoza JL, Okumura H, Yoshida T, Kuzushima K, Nakao S.

J Clin Virol. 2016 Jul;80:82-6. doi: 10.1016/j.jcv.2016.04.020. Epub 2016 May 6.

PMID:
27218416
8.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

9.

Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia.

Tanaka H, Fujiwara H, Ochi F, Tanimoto K, Casey N, Okamoto S, Mineno J, Kuzushima K, Shiku H, Sugiyama T, Barrett AJ, Yasukawa M.

Clin Cancer Res. 2016 Sep 1;22(17):4405-16. doi: 10.1158/1078-0432.CCR-15-2714. Epub 2016 Apr 18.

10.

Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated Vα24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells.

Kitayama S, Zhang R, Liu TY, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S.

Stem Cell Reports. 2016 Feb 9;6(2):213-27. doi: 10.1016/j.stemcr.2016.01.005.

11.

Identification of a naturally processed HLA-Cw7-binding peptide that cross-reacts with HLA-A24-restricted ovarian cancer-specific CTLs.

Yamada E, Demachi-Okamura A, Kondo S, Akatsuka Y, Suzuki S, Shibata K, Kikkawa F, Kuzushima K.

Tissue Antigens. 2015 Sep;86(3):164-71. doi: 10.1111/tan.12607. Epub 2015 Jul 28.

PMID:
26216489
12.

Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.

Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Leukemia. 2015 Dec;29(12):2393-401. doi: 10.1038/leu.2015.155. Epub 2015 Jun 24.

PMID:
26104661
13.

Induction of HLA-B*40:02-restricted T cells possessing cytotoxic and suppressive functions against haematopoietic progenitor cells from a patient with severe aplastic anaemia.

Inaguma Y, Akatsuka Y, Hosokawa K, Maruyama H, Okamoto A, Katagiri T, Shiraishi K, Murayama Y, Tsuzuki-Iba S, Mizutani Y, Nishii C, Yamamoto N, Demachi-Okamura A, Kuzushima K, Ogawa S, Emi N, Nakao S.

Br J Haematol. 2016 Jan;172(1):131-4. doi: 10.1111/bjh.13464. Epub 2015 Apr 30. No abstract available.

PMID:
25929998
14.

Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells.

Zhang R, Liu TY, Senju S, Haruta M, Hirosawa N, Suzuki M, Tatsumi M, Ueda N, Maki H, Nakatsuka R, Matsuoka Y, Sasaki Y, Tsuzuki S, Nakanishi H, Araki R, Abe M, Akatsuka Y, Sakamoto Y, Sonoda Y, Nishimura Y, Kuzushima K, Uemura Y.

Cancer Immunol Res. 2015 Jun;3(6):668-77. doi: 10.1158/2326-6066.CIR-14-0117. Epub 2015 Feb 11.

15.

Increased T-cell responses to Epstein-Barr virus with high viral load in patients with Epstein-Barr virus-positive diffuse large B-cell lymphoma.

Morishima S, Nakamura S, Yamamoto K, Miyauchi H, Kagami Y, Kinoshita T, Onoda H, Yatabe Y, Ito M, Miyamura K, Nagai H, Moritani S, Sugiura I, Tsushita K, Mihara H, Ohbayashi K, Iba S, Emi N, Okamoto M, Iwata S, Kimura H, Kuzushima K, Morishima Y.

Leuk Lymphoma. 2015 Apr;56(4):1072-8. doi: 10.3109/10428194.2014.938326. Epub 2014 Aug 13.

PMID:
24975317
16.

Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation.

Ito T, Kawazu H, Murata T, Iwata S, Arakawa S, Sato Y, Kuzushima K, Goshima F, Kimura H.

Cancer Med. 2014 Aug;3(4):787-95. doi: 10.1002/cam4.256. Epub 2014 May 3.

17.

Gene-modified human α/β-T cells expressing a chimeric CD16-CD3ζ receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy.

Ochi F, Fujiwara H, Tanimoto K, Asai H, Miyazaki Y, Okamoto S, Mineno J, Kuzushima K, Shiku H, Barrett J, Ishii E, Yasukawa M.

Cancer Immunol Res. 2014 Mar;2(3):249-62. doi: 10.1158/2326-6066.CIR-13-0099-T. Epub 2014 Jan 3.

18.

Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H.

Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A, Tsujikawa J, Demachi-Okamura A, Hiramatsu K, Saji H, Yamamoto Y, Yamamoto N, Nishimura Y, Takahashi T, Kuzushima K, Emi N, Akatsuka Y.

Gene Ther. 2014 Jun;21(6):575-84. doi: 10.1038/gt.2014.30. Epub 2014 Apr 3.

PMID:
24694533
19.

Adoptive transfer of genetically engineered WT1-specific cytotoxic T lymphocytes does not induce renal injury.

Asai H, Fujiwara H, Kitazawa S, Kobayashi N, Ochi T, Miyazaki Y, Ochi F, Akatsuka Y, Okamoto S, Mineno J, Kuzushima K, Ikeda H, Shiku H, Yasukawa M.

J Hematol Oncol. 2014 Jan 6;7:3. doi: 10.1186/1756-8722-7-3.

20.

An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules.

Kondo S, Demachi-Okamura A, Hirosawa T, Maki H, Fujita M, Uemura Y, Akatsuka Y, Yamamoto E, Shibata K, Ino K, Kikkawa F, Kuzushima K.

Hum Immunol. 2013 Sep;74(9):1103-10. doi: 10.1016/j.humimm.2013.06.030. Epub 2013 Jun 24.

PMID:
23806269
21.

Development of a novel redirected T-cell-based adoptive immunotherapy targeting human telomerase reverse transcriptase for adult T-cell leukemia.

Miyazaki Y, Fujiwara H, Asai H, Ochi F, Ochi T, Azuma T, Ishida T, Okamoto S, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2013 Jun 13;121(24):4894-901. doi: 10.1182/blood-2012-11-465971. Epub 2013 May 2.

PMID:
23641014
22.

Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor.

Asai H, Fujiwara H, An J, Ochi T, Miyazaki Y, Nagai K, Okamoto S, Mineno J, Kuzushima K, Shiku H, Inoue H, Yasukawa M.

PLoS One. 2013;8(2):e56820. doi: 10.1371/journal.pone.0056820. Epub 2013 Feb 18.

23.

A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.

Okamoto S, Amaishi Y, Goto Y, Ikeda H, Fujiwara H, Kuzushima K, Yasukawa M, Shiku H, Mineno J.

Mol Ther Nucleic Acids. 2012 Dec 18;1:e63. doi: 10.1038/mtna.2012.52.

24.

Recognition of a natural WT1 epitope by a modified WT1 peptide-specific T-cell receptor.

Tamanaka T, Oka Y, Fujiki F, Tsuboi A, Katsuhara A, Nakajima H, Hosen N, Nishida S, Lin YH, Tachino S, Akatsuka Y, Kuzushima K, Oji Y, Kumanogoh A, Sugiyama H.

Anticancer Res. 2012 Dec;32(12):5201-9.

PMID:
23225417
25.

Autophagy creates a CTL epitope that mimics tumor-associated antigens.

Demachi-Okamura A, Torikai H, Akatsuka Y, Miyoshi H, Yoshimori T, Kuzushima K.

PLoS One. 2012;7(10):e47126. doi: 10.1371/journal.pone.0047126. Epub 2012 Oct 11.

26.

Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.

Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K.

J Immunother. 2012 Oct;35(8):598-606.

PMID:
22996365
27.

Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide.

Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E.

Int J Cancer. 2013 Jan 15;132(2):345-54. doi: 10.1002/ijc.27682. Epub 2012 Jul 11.

28.

HLA-restricted presentation of WT1 tumor antigen in B-lymphoblastoid cell lines established using a maxi-EBV system.

Kanda T, Ochi T, Fujiwara H, Yasukawa M, Okamoto S, Mineno J, Kuzushima K, Tsurumi T.

Cancer Gene Ther. 2012 Aug;19(8):566-71. doi: 10.1038/cgt.2012.34. Epub 2012 Jun 22.

PMID:
22722376
29.

HapMap SNP Scanner: an online program to mine SNPs responsible for cell phenotype.

Yamamura T, Hikita J, Bleakley M, Hirosawa T, Sato-Otsubo A, Torikai H, Hamajima T, Nannya Y, Demachi-Okamura A, Maruya E, Saji H, Yamamoto Y, Takahashi T, Emi N, Morishima Y, Kodera Y, Kuzushima K, Riddell SR, Ogawa S, Akatsuka Y.

Tissue Antigens. 2012 Aug;80(2):119-25. doi: 10.1111/j.1399-0039.2012.01883.x. Epub 2012 May 8.

30.

Intracellular interferon-γ staining analysis of donor-specific T-cell responses in liver transplant recipients.

Okanami Y, Tsujimura K, Mizuno S, Tabata M, Isaji S, Akatsuka Y, Kuzushima K, Takahashi T, Uemoto S.

Transplant Proc. 2012 Mar;44(2):548-54. doi: 10.1016/j.transproceed.2011.11.007.

PMID:
22410067
31.

IL-21 can supplement suboptimal Lck-independent MAPK activation in a STAT-3-dependent manner in human CD8(+) T cells.

Imataki O, Ansén S, Tanaka M, Butler MO, Berezovskaya A, Milstein MI, Kuzushima K, Nadler LM, Hirano N.

J Immunol. 2012 Feb 15;188(4):1609-19. doi: 10.4049/jimmunol.1003446. Epub 2012 Jan 11.

32.

Aurora kinase A-specific T-cell receptor gene transfer redirects T lymphocytes to display effective antileukemia reactivity.

Nagai K, Ochi T, Fujiwara H, An J, Shirakata T, Mineno J, Kuzushima K, Shiku H, Melenhorst JJ, Gostick E, Price DA, Ishii E, Yasukawa M.

Blood. 2012 Jan 12;119(2):368-76. doi: 10.1182/blood-2011-06-360354. Epub 2011 Oct 24.

PMID:
22025529
33.

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.

Ochi T, Fujiwara H, Okamoto S, An J, Nagai K, Shirakata T, Mineno J, Kuzushima K, Shiku H, Yasukawa M.

Blood. 2011 Aug 11;118(6):1495-503. doi: 10.1182/blood-2011-02-337089. Epub 2011 Jun 14.

PMID:
21673345
34.

A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate.

Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Kondo T, Maekawa R, Takahara M, Nieda M, Kuzushima K, Ishikawa T, Uchiyama T.

Br J Haematol. 2011 Jun;153(6):796-9. doi: 10.1111/j.1365-2141.2010.08490.x. Epub 2011 Apr 8. No abstract available.

PMID:
21477159
35.

A novel animal model of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in humanized mice.

Sato K, Misawa N, Nie C, Satou Y, Iwakiri D, Matsuoka M, Takahashi R, Kuzushima K, Ito M, Takada K, Koyanagi Y.

Blood. 2011 May 26;117(21):5663-73. doi: 10.1182/blood-2010-09-305979. Epub 2011 Apr 5.

PMID:
21467545
36.

Mismatched human leukocyte antigen class II-restricted CD8⁺ cytotoxic T cells may mediate selective graft-versus-leukemia effects following allogeneic hematopoietic cell transplantation.

Hirosawa T, Torikai H, Yanagisawa M, Kamei M, Imahashi N, Demachi-Okamura A, Tanimoto M, Shiraishi K, Ito M, Miyamura K, Shibata K, Kikkawa F, Morishima Y, Takahashi T, Emi N, Kuzushima K, Akatsuka Y.

Cancer Sci. 2011 Jul;102(7):1281-6. doi: 10.1111/j.1349-7006.2011.01949.x. Epub 2011 May 9.

37.

Activation of T-cell receptor signaling in peripheral T-cell lymphoma cells plays an important role in the development of lymphoma-associated hemophagocytosis.

An J, Fujiwara H, Suemori K, Niiya T, Azuma T, Tanimoto K, Ochi T, Akatsuka Y, Mineno J, Ozawa H, Ishikawa F, Kuzushima K, Yasukawa M.

Int J Hematol. 2011 Feb;93(2):176-185. doi: 10.1007/s12185-010-0758-7. Epub 2011 Jan 13.

PMID:
21229399
38.

Generation of antigen-specific cytotoxic T lymphocytes using a leukemic plasmacytoid dendritic cell line as antigen presenting cells.

Yamahira A, Narita M, Nakamura T, Watanabe N, Kaji M, Taniguchi T, Hashimoto S, Furukawa T, Toba K, Aizawa Y, Kuzushima K, Takahashi M.

Leuk Res. 2011 Jun;35(6):793-9. doi: 10.1016/j.leukres.2010.12.003. Epub 2011 Jan 8.

PMID:
21216464
39.

Cross-priming of CD8(+) T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia.

Kitawaki T, Kadowaki N, Fukunaga K, Kasai Y, Maekawa T, Ohmori K, Itoh T, Shimizu A, Kuzushima K, Kondo T, Ishikawa T, Uchiyama T.

Exp Hematol. 2011 Apr;39(4):424-433.e2. doi: 10.1016/j.exphem.2011.01.001. Epub 2011 Jan 7.

40.

Kinetics of Epstein-Barr virus load and virus-specific CD8+ T cells in acute infectious mononucleosis.

Hoshino Y, Nishikawa K, Ito Y, Kuzushima K, Kimura H.

J Clin Virol. 2011 Mar;50(3):244-6. doi: 10.1016/j.jcv.2010.11.017. Epub 2010 Dec 24.

PMID:
21185773
41.

Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.

Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E.

Cancer Immun. 2009 Oct 1;9:8.

42.

Clinical efficacy of WT1 peptide vaccination in patients with acute myelogenous leukemia and myelodysplastic syndrome.

Yasukawa M, Fujiwara H, Ochi T, Suemori K, Narumi H, Azuma T, Kuzushima K.

Am J Hematol. 2009 May;84(5):314-5. doi: 10.1002/ajh.21387. No abstract available.

43.

Aurora-A kinase: a novel target of cellular immunotherapy for leukemia.

Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M.

Blood. 2009 Jan 1;113(1):66-74. doi: 10.1182/blood-2008-06-164889. Epub 2008 Sep 26.

PMID:
18820130
44.

HapMap scanning of novel human minor histocompatibility antigens.

Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, Takahashi T, Yazaki M, Morishima S, Tsujimura K, Miyamura K, Ito T, Togari H, Riddell SR, Kodera Y, Morishima Y, Takahashi T, Kuzushima K, Ogawa S, Akatsuka Y.

Blood. 2009 May 21;113(21):5041-8. doi: 10.1182/blood-2008-07-171678. Epub 2008 Sep 22.

45.

Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells.

Demachi-Okamura A, Ito Y, Akatsuka Y, Tsujimura K, Morishima Y, Takahashi T, Kuzushima K.

Cancer Sci. 2008 Aug;99(8):1633-42. doi: 10.1111/j.1349-7006.2008.00852.x.

46.

Human TSLP directly enhances expansion of CD8+ T cells.

Akamatsu T, Watanabe N, Kido M, Saga K, Tanaka J, Kuzushima K, Nishio A, Chiba T.

Clin Exp Immunol. 2008 Oct;154(1):98-106. doi: 10.1111/j.1365-2249.2008.03731.x. Epub 2008 Aug 22.

47.

CD137-guided isolation and expansion of antigen-specific CD8 cells for potential use in adoptive immunotherapy.

Watanabe K, Suzuki S, Kamei M, Toji S, Kawase T, Takahashi T, Kuzushima K, Akatsuka Y.

Int J Hematol. 2008 Oct;88(3):311-320. doi: 10.1007/s12185-008-0134-z. Epub 2008 Aug 5.

PMID:
18677654
48.

Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen.

Shimato S, Natsume A, Wakabayashi T, Tsujimura K, Nakahara N, Ishii J, Ito M, Akatsuka Y, Kuzushima K, Yoshida J.

J Neurosurg. 2008 Jul;109(1):117-22. doi: 10.3171/JNS/2008/109/7/0117.

PMID:
18590440
49.

Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.

Torikai H, Akatsuka Y, Yatabe Y, Morishima Y, Kodera Y, Kuzushima K, Takahashi T.

Int J Hematol. 2008 Jun;87(5):467-473. doi: 10.1007/s12185-008-0076-5. Epub 2008 Apr 15.

PMID:
18414982
50.

The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.

Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J.

Int J Cancer. 2008 Jun 1;122(11):2542-53. doi: 10.1002/ijc.23407.

Supplemental Content

Loading ...
Support Center